Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials
Sarah C. Rutherford(NewYork–Presbyterian Hospital), John P. Leonard(New York University), Cara A. Rosenbaum(Cornell University), Sin‐Ho Jung(Duke University), Vaishalee P. Kenkre(University of Wisconsin–Madison), Jonathan W. Friedberg(University of Rochester), Peter Martin(Northwestern University), Michael LeBlanc(Fred Hutch Cancer Center), Betsy LaPlant(Mayo Clinic), Mazyar Shadman(University of Washington), Levi Pederson(Mayo Clinic in Florida), Paul M. Barr(University of Rochester Medical Center), Kristie A. Blum(Emory University), Travis Dockter(Mayo Clinic), Brad S. Kahl(UW Health University Hospital), Fangxin Hong(Dana-Farber Cancer Institute), Nancy L. Bartlett(Washington University in St. Louis), Chaitra S. Ujjani(Fred Hutch Cancer Center), Bruce D. Cheson(Center for Cancer and Blood Disorders), Joseph M. Unger(Fred Hutch Cancer Center), Hongli Li(Shanghai University of Traditional Chinese Medicine), Jun Yin(Mayo Clinic), Sumithra J. Mandrekar(Mayo Clinic), Barbara Grant(University of Vermont), Gabriela Perez Burbano(National Cancer Institute)
Cited by 18
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k